Literature DB >> 19740319

A novel synthetic adjuvant enhances dendritic cell function.

Karen S M Phillipps1, Michelle N Wykes, Xue Q Liu, Melissa Brown, Joanne Blanchfield, Istvan Toth.   

Abstract

The lipid core peptide (LCP) is a novel, synthetic, self-adjuvanted vaccine delivery system that neatly incorporates the adjuvant, carrier and antigenic peptides of a vaccine into a single molecular entity. This system has been previously shown to efficiently deliver vaccines and induce immunity. Because adjuvants target sentinels of the immune response, such as dendritic cells (DCs), that are widely distributed throughout the body to initiate specific immune responses, we investigated the effects of the adjuvant on DCs. Here we show that LCP targets vaccines to DCs and induces their activation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19740319      PMCID: PMC2753928          DOI: 10.1111/j.1365-2567.2008.03038.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  37 in total

1.  Cutting edge: functional interactions between toll-like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin.

Authors:  A M Hajjar; D S O'Mahony; A Ozinsky; D M Underhill; A Aderem; S J Klebanoff; C B Wilson
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

2.  A lipid core peptide construct containing a conserved region determinant of the group A streptococcal M protein elicits heterologous opsonic antibodies.

Authors:  Colleen Olive; Michael R Batzloff; Anikó Horváth; Allan Wong; Timothy Clair; Penny Yarwood; Istvan Toth; Michael F Good
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

3.  Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products.

Authors:  E Lien; T J Sellati; A Yoshimura; T H Flo; G Rawadi; R W Finberg; J D Carroll; T Espevik; R R Ingalls; J D Radolf; D T Golenbock
Journal:  J Biol Chem       Date:  1999-11-19       Impact factor: 5.157

4.  Evidence for an accessory protein function for Toll-like receptor 1 in anti-bacterial responses.

Authors:  D H Wyllie; E Kiss-Toth; A Visintin; S C Smith; S Boussouf; D M Segal; G W Duff; S K Dower
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

5.  Anatomic location and T-cell stimulatory functions of mouse dendritic cell subsets defined by CD4 and CD8 expression.

Authors:  Alexander D McLellan; Michaela Kapp; Andreas Eggert; Christian Linden; Ursula Bommhardt; Eva-B Bröcker; Ulrike Kämmerer; Eckhart Kämpgen
Journal:  Blood       Date:  2002-03-15       Impact factor: 22.113

6.  Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins.

Authors:  Osamu Takeuchi; Shintaro Sato; Takao Horiuchi; Katsuaki Hoshino; Kiyoshi Takeda; Zhongyun Dong; Robert L Modlin; Shizuo Akira
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

7.  Toll-like receptor 2 agonist Pam3CSK4 enhances the induction of antigen-specific tolerance via the sublingual route.

Authors:  V Lombardi; L Van Overtvelt; S Horiot; H Moussu; H Chabre; A Louise; A-M Balazuc; L Mascarell; P Moingeon
Journal:  Clin Exp Allergy       Date:  2008-07-17       Impact factor: 5.018

Review 8.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

9.  The dendritic cell receptor for endocytosis, DEC-205, can recycle and enhance antigen presentation via major histocompatibility complex class II-positive lysosomal compartments.

Authors:  K Mahnke; M Guo; S Lee; H Sepulveda; S L Swain; M Nussenzweig; R M Steinman
Journal:  J Cell Biol       Date:  2000-10-30       Impact factor: 10.539

10.  Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential toll-like receptor ligation.

Authors:  André Boonstra; Carine Asselin-Paturel; Michel Gilliet; Chad Crain; Giorgio Trinchieri; Yong-Jun Liu; Anne O'Garra
Journal:  J Exp Med       Date:  2003-01-06       Impact factor: 14.307

View more
  10 in total

Review 1.  Use of defined TLR ligands as adjuvants within human vaccines.

Authors:  Malcolm S Duthie; Hillarie Plessner Windish; Christopher B Fox; Steven G Reed
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Design, synthesis and characterisation of mannosylated ovalbumin lipid core peptide self-adjuvanting vaccine delivery system.

Authors:  Pavla Simerska; Zyta Maria Ziora; Vincent Fagan; Daryn Goodwin; Farrah Edrous; Istvan Toth
Journal:  Drug Deliv Transl Res       Date:  2014-06       Impact factor: 4.617

Review 3.  Supramolecular peptide vaccines: tuning adaptive immunity.

Authors:  Yi Wen; Joel H Collier
Journal:  Curr Opin Immunol       Date:  2015-07-08       Impact factor: 7.486

4.  HBVsvp-Pulsed Dendritic Cell Immunotherapy Induces Th1 Polarization and Hepatitis B Virus-Specific Cytotoxic T Lymphocytes Production.

Authors:  Mohamed M S Farag; Reda A Suef; Ghada M Al-Toukhy; Mohamed A Selim; Mostafa A Elbahnasawy; Nahla El Sharkawy; Sameera Ezzat; Nashwa Shebl; Mohamed T M Mansour
Journal:  Infect Drug Resist       Date:  2020-08-05       Impact factor: 4.003

Review 5.  Designer lipids for drug delivery: from heads to tails.

Authors:  Aditya G Kohli; Paul H Kierstead; Vincent J Venditto; Colin L Walsh; Francis C Szoka
Journal:  J Control Release       Date:  2014-05-06       Impact factor: 9.776

6.  Vaccination with lipid core peptides fails to induce epitope-specific T cell responses but confers non-specific protective immunity in a malaria model.

Authors:  Simon H Apte; Penny L Groves; Mariusz Skwarczynski; Yoshio Fujita; Chenghung Chang; Istvan Toth; Denise L Doolan
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

7.  Chemically Modified Bacterial Sacculi as a Vaccine Microparticle Scaffold.

Authors:  Payton A-B Weidenbacher; Frances P Rodriguez-Rivera; Mrinmoy Sanyal; Joshua A Visser; Jonathan Do; Carolyn R Bertozzi; Peter S Kim
Journal:  ACS Chem Biol       Date:  2022-04-12       Impact factor: 4.634

Review 8.  Immunostimulation by synthetic lipopeptide-based vaccine candidates: structure-activity relationships.

Authors:  Mehfuz Zaman; Istvan Toth
Journal:  Front Immunol       Date:  2013-10-09       Impact factor: 7.561

Review 9.  Targeting TLR2 for vaccine development.

Authors:  Afonso P Basto; Alexandre Leitão
Journal:  J Immunol Res       Date:  2014-06-26       Impact factor: 4.818

Review 10.  The application of self-assembled nanostructures in peptide-based subunit vaccine development.

Authors:  Guangzu Zhao; Saranya Chandrudu; Mariusz Skwarczynski; Istvan Toth
Journal:  Eur Polym J       Date:  2017-02-10       Impact factor: 4.598

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.